Antihepatitis C virus therapy in liver transplanted patients

Hepatitis C virus (HCV) management in the transplant setting is still an open issue. The therapeutic strategies being addressed include: (a) pre-transplant prophylaxis (to prevent the infection of the transplanted organ); (b) post-transplant prophylaxis (to reduce the possibility of developing acute hepatitis); (c) management once the chronic disease has already set in and stabilized. Combination therapy with peginterferon alfa-2b plus ribavirin seems to play an important role for patients with established recurrent hepatitis C.